rs780615798
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1PP4_ModeratePM2_SupportingPS1_SupportingPM3
This summary comes from the ClinGen Evidence Repository: The NM_000203.5:c.385+1G>C variant in IDUA occurs within the canonical splice donor site of intron 3. It is predicted to cause skipping of biologically-relevant-exon 3 out of 14 exons, resulting in a frameshift leading to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (PVS1). Two patients from a Mexican cohort have been reported with "low or no activity of α-L-iduronidase" and treated with enzyme replacement therapy. One patient from Spain was reported with clinical features consistent with MPS1, elevated urine GAGs, and deficient IDUA activity, meeting three criteria for PP4 (PP4_Moderate). Both of the individuals from Mexico are compound heterozygous for the variant and another variant in IDUA that has been classified as pathogenic by the ClinGen LD VCEP - c.46_57del ((p.Ser16_Ala19del) (ClinVar variation ID: 92643) in one patient and c.1598C>G (p.Pro533Arg) (ClinVar variation ID: 11910) in the other patient. Phase was not confirmed in either patient (PMID:25098213) (2 x 0.5 points = 1 point) (PM3). The patient from Spain is compound heterozygous for the variant and c.655G>C (p.Gy219Arg). The allelic data from this patient will be used in the classification of p.Gly219 Arg and is not included here to avoid circular logic. The variant is absent in gnomAD v4.1.0. (PM2_Supporting). Another variant at the same position, c.385+1G>A (ClinGen Allele Registry ID: CA355961228), has been classified as pathogenic by the ClinGen LD VCEP (PS1_Supporting, PMID:37352859). In summary, this variant meets the criteria to be classified as pathogenic. IDUA-specific ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Diseases Variant Curation Expert Panel (Specifications version 1.0.0: PVS1, PM3, PS1_Supporting, PM2_Supporting.(Classification approved by the ClinGen Lysosomal Diseases Variant Curation Expert Panel on December 5, 2024) LINK:https://erepo.genome.network/evrepo/ui/classification/CA2801887/MONDO:0001586/091
Frequency
Consequence
NM_000203.5 splice_donor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 34
GnomAD3 exomes AF: 0.00000401 AC: 1AN: 249514Hom.: 0 AF XY: 0.00000738 AC XY: 1AN XY: 135482
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 34
ClinVar
Submissions by phenotype
Mucopolysaccharidosis type 1 Pathogenic:3
The NM_000203.5:c.385+1G>C variant in IDUA occurs within the canonical splice donor site of intron 3. It is predicted to cause skipping of biologically-relevant-exon 3 out of 14 exons, resulting in a frameshift leading to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (PVS1). Two patients from a Mexican cohort have been reported with "low or no activity of α-L-iduronidase" and treated with enzyme replacement therapy. One patient from Spain was reported with clinical features consistent with MPS1, elevated urine GAGs, and deficient IDUA activity, meeting three criteria for PP4 (PP4_Moderate). Both of the individuals from Mexico are compound heterozygous for the variant and another variant in IDUA that has been classified as pathogenic by the ClinGen LD VCEP - c.46_57del ((p.Ser16_Ala19del) (ClinVar variation ID: 92643) in one patient and c.1598C>G (p.Pro533Arg) (ClinVar variation ID: 11910) in the other patient. Phase was not confirmed in either patient (PMID: 25098213) (2 x 0.5 points = 1 point) (PM3). The patient from Spain is compound heterozygous for the variant and c.655G>C (p.Gy219Arg). The allelic data from this patient will be used in the classification of p.Gly219 Arg and is not included here to avoid circular logic. The variant is absent in gnomAD v4.1.0. (PM2_Supporting). Another variant at the same position, c.385+1G>A (ClinGen Allele Registry ID: CA355961228), has been classified as pathogenic by the ClinGen LD VCEP (PS1_Supporting, PMID: 37352859). In summary, this variant meets the criteria to be classified as pathogenic. IDUA-specific ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Diseases Variant Curation Expert Panel (Specifications version 1.0.0: PVS1, PM3, PS1_Supporting, PM2_Supporting. (Classification approved by the ClinGen Lysosomal Diseases Variant Curation Expert Panel on December 5, 2024) -
- -
This sequence change affects a donor splice site in intron 3 of the IDUA gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in IDUA are known to be pathogenic (PMID: 11735025, 21480867). This variant is present in population databases (rs780615798, gnomAD no frequency). Disruption of this splice site has been observed in individuals with Hurler or Hurler/Scheie syndrome (PMID: 25098213). ClinVar contains an entry for this variant (Variation ID: 551966). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. -
not provided Pathogenic:1
- -
Hurler syndrome Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at